Genomics in precision medicine
Keywords:
precision medicine, genetic makeup, diseases, diagnosisAbstract
The term Precision Medicine (PM) gained significant attention in the field of drug discovery. The roots of PM can be traced back even before the start of Human Genome Project (in the early 2000s) but came into existence only by 2010. PM is a preventative strategy that focuses on improved patient care by taking account on variability in genes, environment, and lifestyle for each individual. PM is a long-term endeavour, including the National Institute of Health (NIH) and multiple other research centres were pioneers in funding and conducting cutting edge research related to PM. Knowing the genetic makeup of an individual will help us better understand and predict the risk of disease, this will further aid in personalised diagnosis and treatment strategies. Although there has been significant number of research articles available on PM, however to the best of my knowledge they do not emphasise much on the reasons why PM has not been the choice for disease diagnosis and patient care. Therefore, this article will explain how PM will transform the future of heath care as we know it today. In addition, this article also discusses on factors that will aid in the development of PM.
Downloads
References
S. J. Aronson and H. L. Rehm, “Building the foundation for genomics in precision medicine,” Nature, vol. 526, no. 7573. Nature Publishing Group, pp. 336–342, Oct. 14, 2015. doi: 10.1038/nature15816.
J. Bluett and A. Barton, “Precision Medicine in Rheumatoid Arthritis,” Rheumatic Disease Clinics of North America, vol. 43, no. 3, pp. 377–387, Aug. 2017, doi: 10.1016/j.rdc.2017.04.008.
H. Collins, S. Calvo, K. Greenberg, L. Forman Neall, and S. Morrison, “Information Needs in the Precision Medicine Era: How Genetics Home Reference Can Help,” interactive Journal of Medical Research, vol. 5, no. 2, p. e13, Apr. 2016, doi: 10.2196/ijmr.5199.
H. R. Warren et al., “Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk,” Nature Genetics, vol. 49, no. 3, pp. 403–415, Mar. 2017, doi: 10.1038/ng.3768.
E. Zeggini, A. L. Gloyn, A. C. Barton, and L. v. Wain, “Translational genomics and precision medicine: Moving from the lab to the clinic,” Science (1979), vol. 365, no. 6460, pp. 1409–1413, Sep. 2019, doi: 10.1126/science.aax4588.
F. Carrasco-Ramiro, R. Peiró-Pastor, and B. Aguado, “Human genomics projects and precision medicine,” Gene Therapy, vol. 24, no. 9. Nature Publishing Group, pp. 551–561, Sep. 01, 2017. doi: 10.1038/gt.2017.77.
M. Dixit, T. Doan, R. Kirschner, and N. Dixit, “Significant acute kidney injury due to non-steroidal antiinflammatory drugs: Inpatient setting,” Pharmaceuticals, vol. 3, no. 4, pp. 1279–1285, 2010, doi: 10.3390/ph3041279.
L. R. Cardon and T. Harris, “Precision medicine, genomics and drug discovery,” Human Molecular Genetics, vol. 25, no. R2. Oxford University Press, pp. R166–R172, Oct. 01, 2016. doi: 10.1093/hmg/ddw246.
P.-A. Gourraud et al., “Precision medicine in chronic disease management: The multiple sclerosis BioScreen,” Annals of Neurology, vol. 76, no. 5, pp. 633–642, Nov. 2014, doi: 10.1002/ana.24282.
Z. Ahmed, S. Zeeshan, D. Mendhe, and X. Dong, “Human gene and disease associations for clinical‐genomics and precision medicine research,” Clinical and Translational Medicine, vol. 10, no. 1, pp. 297–318, Mar. 2020, doi: 10.1002/ctm2.28.
“Role of NGS in Precision medicine”.
M. Gwinn et al., “Horizon scanning for new genomic tests,” Genetics in Medicine, vol. 13, no. 2, pp. 161–165, Feb. 2011, doi: 10.1097/GIM.0b013e3182011661.
T. A. Beery, “Genetic and genomic testing in clinical practice: What you need to know,” Rehabilitation Nursing, vol. 39, no. 2, pp. 70–75, Mar. 2014, doi: 10.1002/rnj.126.
J. Xu et al., “Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives,” Human Genetics, vol. 138, no. 2. Springer Verlag, pp. 109–124, Feb. 08, 2019. doi: 10.1007/s00439-019-01970-5.
N. I. Simonds et al., “Comparative effectiveness research in cancer genomics and precision medicine: Current landscape and future prospects,” Journal of the National Cancer Institute, vol. 105, no. 13. pp. 929–936, Jul. 03, 2013. doi: 10.1093/jnci/djt108.
M. H. Harris et al., “Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors,” JAMA Oncology, vol. 2, no. 5, pp. 608–615, May 2016, doi: 10.1001/jamaoncol.2015.5689.
A. Śliwczyński and E. Orlewska, “Precision medicine for managing chronic diseases,” Polskie Archiwum Medycyny Wewnetrznej, vol. 126, no. 9. Medycyna Praktyczna, pp. 681–687, 2016. doi: 10.20452/pamw.3503.
J. A. Leopold, B. A. Maron, and J. Loscalzo, “The application of big data to cardiovascular disease: Paths to precision medicine,” Journal of Clinical Investigation, vol. 130, no. 1, pp. 29–38, Jan. 2020, doi: 10.1172/JCI129203.
A. Sivadas and V. Scaria, “Population-scale genomics—Enabling precision public health,” 2019, pp. 119–161. doi: 10.1016/bs.adgen.2018.09.001.
M. J. Khoury et al., “From public health genomics to precision public health: A 20-year journey,” Genetics in Medicine, vol. 20, no. 6. Nature Publishing Group, pp. 574–582, Jun. 01, 2018. doi: 10.1038/gim.2017.211.
Y. Xue et al., “Precision Medicine: What Challenges Are We Facing?,” Genomics, Proteomics and Bioinformatics, vol. 14, no. 5. Beijing Genomics Institute, pp. 253–261, Oct. 01, 2016. doi: 10.1016/j.gpb.2016.10.001.
V. M. Yeh et al., “Can precision medicine actually help people like me? African American and Hispanic perspectives on the benefits and barriers of precision medicine,” Ethnicity and Disease, vol. 30. Ethnicity and Disease, Inc., pp. 149–158, 2020. doi: 10.18865/ed.30.S1.149.
M. J. Khoury and K. E. Holt, “The impact of genomics on precision public health: beyond the pandemic,” Genome Medicine, vol. 13, no. 1. BioMed Central Ltd, Dec. 01, 2021. doi: 10.1186/s13073-021-00886-y.
M. Garland, J. J. Yim, and M. Bogyo, “A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application,” Cell Chemical Biology, vol. 23, no. 1. Elsevier Ltd, pp. 122–136, Jan. 21, 2016. doi: 10.1016/j.chembiol.2015.12.003.
G. Pirovano, T. C. Wilson, and T. Reiner, “Auger: The future of precision medicine,” Nuclear Medicine and Biology, vol. 96–97, pp. 50–53, May 2021, doi: 10.1016/j.nucmedbio.2021.03.002.
S. M. Sisodiya, “Precision medicine and therapies of the future,” Epilepsia, vol. 62, no. S2, pp. S90–S105, Mar. 2021, doi: 10.1111/epi.16539.
“Epilepsy in Multiple Sclerosis”.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
